Abstract
Dopamine modulation of excitatory neurotransmission is critical in the control of movement, emotion and reward. In the striatum, medium size spiny neurons (MSNs) are responsible for the integration of cortical and thalamic information that flows through parallel, partly overlapping, loops and determines adequate experience-dependent responses. Dopamine acts on MSNs through two sets of G protein-coupled receptors (GPCRs), the D1-like and D2-like receptors, which can have opposing or synergistic downstream effects. Notably, these two types of striatal dopamine receptors are segregated into the striatonigral (direct) and striatopallidal (indirect) projecting neurons. Thus, dopamine receptor expression determines the morphological and functional neuronal phenotype of MSNs. Moreover, dopamine regulates glutamatergic corticostriatal transmission, critically controlling the induction of long-term potentiation and long-term depression at these synapses, regulating striatal synaptic plasticity. In addition to dopamine receptors, the induction and expression of plasticity mechanisms is regulated by other GPCRs, most importantly adenosine A2A receptors, metabotropic glutamate mGluR5 receptors and endocannabinoid CB1 receptors. This review focuses on synaptic modulation and plasticity on excitatory corticostriatal synapses by GPCRs.
Keywords: Dopamine, glutamate, GPCR, LTP, LTD, Parkinson Disease, plasticity, striatum
CNS & Neurological Disorders - Drug Targets
Title: Regulation of Corticostriatal Synaptic Plasticity by G Protein-Coupled Receptors
Volume: 9 Issue: 5
Author(s): Rakel Lopez de Maturana and Rosario Sanchez-Pernaute
Affiliation:
Keywords: Dopamine, glutamate, GPCR, LTP, LTD, Parkinson Disease, plasticity, striatum
Abstract: Dopamine modulation of excitatory neurotransmission is critical in the control of movement, emotion and reward. In the striatum, medium size spiny neurons (MSNs) are responsible for the integration of cortical and thalamic information that flows through parallel, partly overlapping, loops and determines adequate experience-dependent responses. Dopamine acts on MSNs through two sets of G protein-coupled receptors (GPCRs), the D1-like and D2-like receptors, which can have opposing or synergistic downstream effects. Notably, these two types of striatal dopamine receptors are segregated into the striatonigral (direct) and striatopallidal (indirect) projecting neurons. Thus, dopamine receptor expression determines the morphological and functional neuronal phenotype of MSNs. Moreover, dopamine regulates glutamatergic corticostriatal transmission, critically controlling the induction of long-term potentiation and long-term depression at these synapses, regulating striatal synaptic plasticity. In addition to dopamine receptors, the induction and expression of plasticity mechanisms is regulated by other GPCRs, most importantly adenosine A2A receptors, metabotropic glutamate mGluR5 receptors and endocannabinoid CB1 receptors. This review focuses on synaptic modulation and plasticity on excitatory corticostriatal synapses by GPCRs.
Export Options
About this article
Cite this article as:
Lopez de Maturana Rakel and Sanchez-Pernaute Rosario, Regulation of Corticostriatal Synaptic Plasticity by G Protein-Coupled Receptors, CNS & Neurological Disorders - Drug Targets 2010; 9 (5) . https://dx.doi.org/10.2174/187152710793361531
DOI https://dx.doi.org/10.2174/187152710793361531 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Medicinal Chemistry Studies for Multitarget Agents-Part II
Current Drug Targets Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Nitric Oxide and Dietary Factors: Part IV Traditional Japanese Food (Soy Products, Fish and Tea)
Vascular Disease Prevention (Discontinued) From Treatment Adherence to Advanced Shared Decision Making: New Professional Strategies and Attitudes in Mental Health Care
Current Clinical Pharmacology The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinsons Disease
Current Clinical Pharmacology Haloperidol Cytotoxicity and Its Relation to Oxidative Stress
Mini-Reviews in Medicinal Chemistry Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Genetic Variants in Diseases of the Extrapyramidal System
Current Genomics Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Optimization of Lentiviral Vectors Generation for Biomedical and Clinical Research Purposes: Contemporary Trends in Technology Development and Applications
Current Gene Therapy Adult Neurogenesis and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Aggregation State and Neurotoxic Properties of Alzheimer β-Amyloid Peptide
Current Protein & Peptide Science The NMDA/D1 Receptor Complex as a New Target in Drug Development
Current Topics in Medicinal Chemistry Prospect of a Dopamine Contribution in the Next Generation of Antidepressant Drugs: The Triple Reuptake Inhibitors
Current Drug Targets Transcranial Magnetic Stimulation of Degenerating Brain: A Comparison of Normal Aging, Alzheimer’s, Parkinson’s and Huntington's Disease
Current Alzheimer Research From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration
CNS & Neurological Disorders - Drug Targets Parallel Roles for Dopamine in Pathological Gambling and Psychostimulant Addiction
Current Drug Abuse Reviews Treating Rapid Cycling Bipolar Disorder with Novel Medications
Current Psychiatry Reviews Nonsynaptic Receptors for GABA and Glutamate
Current Topics in Medicinal Chemistry